---
id: asco-nsclc-2025
title: "Therapy for Stage IV Nonâ€“Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1"
short_title: "ASCO NSCLC Living 2025.1"

organization: American Society of Clinical Oncology
collaborators: null
country: US
url: https://ascopubs.org/doi/10.1200/JCO.24.01509
doi: 10.1200/JCO.24.01509
pmid: null
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - non-small cell lung cancer
  - NSCLC
  - stage IV lung cancer
tags:
  - driver alterations
  - EGFR
  - ALK
  - immunotherapy
  - targeted therapy

publication_date: 2025-07-17
previous_version_date: 2024-05-01
status: current
supersedes: asco-nsclc-2024
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

# ASCO Living Guideline: Stage IV NSCLC with Driver Alterations (Version 2025.1)

## Scope

Updates recommendations for systemic therapy in patients with Stage IV non-small cell lung cancer (NSCLC) who have specific driver alterations (e.g., EGFR, ALK, ROS1, BRAF, MET, RET).

## Key Recommendations

### EGFR Mutations
- **First-line**: Osimertinib remains the preferred first-line therapy for sensitizing EGFR mutations (Exon 19 del/L858R).
- **Update**: Amivantamab plus lazertinib or chemotherapy may be considered in specific settings after progression.

### ALK Rearrangements
- **First-line**: Next-generation ALK inhibitors (alectinib, brigatinib, or lorlatinib) are preferred.

### Other Alterations
- Specific recommendations for ROS1, BRAF V600E, MET exon 14 skipping, and RET fusions are updated to reflect newer clinical trial data.

## Notes

This "living guideline" is updated frequently as soon as significant new evidence impacts clinical practice recommendations.
